| Old | New | Differences | |
|---|---|---|---|
| 1 | - | LAWRENCE J. HOGAN, JR., Governor Ch. 306 | |
| 2 | 1 | ||
| 3 | - | – 1 – | |
| 4 | - | Chapter 306 | |
| 5 | - | (Senate Bill 144) | |
| 6 | 2 | ||
| 7 | - | AN ACT concerning | |
| 3 | + | EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW. | |
| 4 | + | [Brackets] indicate matter deleted from existing law. | |
| 5 | + | Underlining indicates amendments to bill. | |
| 6 | + | Strike out indicates matter stricken from the bill by amendment or deleted from the law by | |
| 7 | + | amendment. | |
| 8 | + | *sb0144* | |
| 8 | 9 | ||
| 9 | - | Health – Authorization to Prescribe and Administer Amygdalin – Repeal | |
| 10 | + | SENATE BILL 144 | |
| 11 | + | J1 2lr0533 | |
| 12 | + | (PRE–FILED) | |
| 13 | + | By: Senator Feldman | |
| 14 | + | Requested: September 22, 2021 | |
| 15 | + | Introduced and read first time: January 12, 2022 | |
| 16 | + | Assigned to: Finance | |
| 17 | + | Committee Report: Favorable | |
| 18 | + | Senate action: Adopted | |
| 19 | + | Read second time: February 17, 2022 | |
| 10 | 20 | ||
| 11 | - | FOR the purpose of repealing certain provisions of law relating to the prescription, | |
| 12 | - | administration, and regulation of amygdalin; and generally relating to amygdalin. | |
| 21 | + | CHAPTER ______ | |
| 13 | 22 | ||
| 14 | - | BY repealing | |
| 15 | - | Article – Health – General | |
| 16 | - | Section 18–302 | |
| 17 | - | Annotated Code of Maryland | |
| 18 | - | (2019 Replacement Volume and 2021 Supplement) | |
| 23 | + | AN ACT concerning 1 | |
| 19 | 24 | ||
| 20 | - | SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, | |
| 21 | - | That the Laws of Maryland read as follows: | |
| 25 | + | Health – Authorization to Prescribe and Administer Amygdalin – Repeal 2 | |
| 22 | 26 | ||
| 23 | - | Article – Health – General | |
| 27 | + | FOR the purpose of repealing certain provisions of law relating to the prescription, 3 | |
| 28 | + | administration, and regulation of amygdalin; and generally relating to amygdalin. 4 | |
| 24 | 29 | ||
| 25 | - | [18–302. | |
| 30 | + | BY repealing 5 | |
| 31 | + | Article – Health – General 6 | |
| 32 | + | Section 18–302 7 | |
| 33 | + | Annotated Code of Maryland 8 | |
| 34 | + | (2019 Replacement Volume and 2021 Supplement) 9 | |
| 26 | 35 | ||
| 27 | - | | |
| 28 | - | ||
| 36 | + | SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 10 | |
| 37 | + | That the Laws of Maryland read as follows: 11 | |
| 29 | 38 | ||
| 30 | - | (b) (1) A hospital or health facility may not restrict or prohibit the use of | |
| 31 | - | amygdalin that a physician, with the consent of a patient, prescribes for or administers to | |
| 32 | - | the patient. | |
| 39 | + | Article – Health – General 12 | |
| 33 | 40 | ||
| 34 | - | (2) (i) The Department may restrict or prohibit the use of amygdalin in | |
| 35 | - | the treatment of a patient if, after a hearing, the Department finds that the manner in | |
| 36 | - | which the amygdalin is prescribed or administered is harmful to the patient. | |
| 41 | + | [18–302. 13 | |
| 37 | 42 | ||
| 38 | - | ( | |
| 39 | - | ||
| 43 | + | (a) Except as provided in subsection (b) of this section, a physician may prescribe 14 | |
| 44 | + | or administer amygdalin to treat cancer. 15 | |
| 40 | 45 | ||
| 41 | - | ( | |
| 42 | - | ||
| 43 | - | ||
| 46 | + | (b) (1) A hospital or health facility may not restrict or prohibit the use of 16 | |
| 47 | + | amygdalin that a physician, with the consent of a patient, prescribes for or administers to 17 | |
| 48 | + | the patient. 18 2 SENATE BILL 144 | |
| 44 | 49 | ||
| 45 | - | SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect | |
| 46 | - | October 1, 2022. | |
| 47 | 50 | ||
| 48 | - | Approved by the Governor, May 12, 2022. | |
| 51 | + | ||
| 52 | + | (2) (i) The Department may restrict or prohibit the use of amygdalin in 1 | |
| 53 | + | the treatment of a patient if, after a hearing, the Department finds that the manner in 2 | |
| 54 | + | which the amygdalin is prescribed or administered is harmful to the patient. 3 | |
| 55 | + | ||
| 56 | + | (ii) The Department shall adopt rules and regulations for hearings 4 | |
| 57 | + | under this paragraph. 5 | |
| 58 | + | ||
| 59 | + | (c) The Department and the State Board of Pharmacy shall regulate the 6 | |
| 60 | + | manufacture, distribution, and sale of amygdalin for use in this State, but only to ensure 7 | |
| 61 | + | that the amygdalin is not adulterated, contaminated by microorganisms, or misbranded.] 8 | |
| 62 | + | ||
| 63 | + | SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 9 | |
| 64 | + | October 1, 2022. 10 | |
| 65 | + | ||
| 66 | + | ||
| 67 | + | ||
| 68 | + | Approved: | |
| 69 | + | ________________________________________________________________________________ | |
| 70 | + | Governor. | |
| 71 | + | ________________________________________________________________________________ | |
| 72 | + | President of the Senate. | |
| 73 | + | ________________________________________________________________________________ | |
| 74 | + | Speaker of the House of Delegates. |